Encouraging preliminary clinical activity of anti-TROP2 ADCs such as sacituzumab govitecan, MK-2870 (sacituzumab tirumotecan), and datopotamab deruxtecan (Dato-DXd) ADC has recently been reported in endometrial as well as ovarian cancer patients [5]. This evidence concerns the gene TACSTD2 and ovarian carcinoma.